When the U.S. Food and Drug Administration issued new guidance earlier this month on how companies who handle human cells, tissues and cellular and tissue-based products should report problems to the agency, it was a recognition that the medical industry is heading deeper into uncharted territory.
Regenerative medicine, gene editing markets are growing
